Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, JL[Lee, J. -L.] | - |
dc.contributor.author | Ahn, JH[Ahn, J. -H.] | - |
dc.contributor.author | Lee, SH[Lee, S. H.] | - |
dc.contributor.author | Kim, TM[Kim, T. M.] | - |
dc.contributor.author | Lee, DH[Lee, D. -H.] | - |
dc.contributor.author | Cho, YM[Cho, Y. M.] | - |
dc.contributor.author | Song, C[Song, C.] | - |
dc.contributor.author | Hong, JH[Hong, J. H.] | - |
dc.contributor.author | Kim, CS[Kim, C. -S.] | - |
dc.contributor.author | Ahn, H[Ahn, H.] | - |
dc.contributor.author | Lim, HY[Lim, H. Y.] | - |
dc.contributor.author | Park, SH[Park, S. H.] | - |
dc.date.accessioned | 2021-08-05T06:56:20Z | - |
dc.date.available | 2021-08-05T06:56:20Z | - |
dc.date.created | 2016-08-06 | - |
dc.date.issued | 2012-08 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/64711 | - |
dc.description.abstract | Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC). Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4 weeks, followed by 2 weeks of rest. The primary end point was overall response rate (RR). Thirty-one eligible patients were enrolled. Twenty-four patients (77%) had prior nephrectomy. By Memorial Sloan-Kettering Cancer Center criteria, 8 patients (26%) had poor risk and 14 (45%) had intermediate risk. Twenty-two patients had papillary renal cell carcinoma (RCC), and three had chromophobe RCC. Eleven patients had partial response with a RR of 36% (95% confidence interval (CI) 19% to 52%) and an additional 17 patients (55%) had stable disease. Median duration of response was 12.7 months (95% CI 6.3-19.1 months), and median progression-free survival was 6.4 months (95% CI 4.2-8.6 months). At a median follow-up duration of 18.7 months (95% CI 13.7-23.7 months), 13 patients (42%) had died, resulting in an estimated median survival of 25.6 months (95% CI 8.4-42.9 months). Toxicity profiles were commensurate with prior reports. Sunitinib has promising activity in patients with nccRCC (NCT01219751). | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject | INTERFERON-ALPHA | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | EFFICACY | - |
dc.subject | TRIAL | - |
dc.subject | E | - |
dc.title | Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, HY[Lim, H. Y.] | - |
dc.contributor.affiliatedAuthor | Park, SH[Park, S. H.] | - |
dc.identifier.doi | 10.1093/annonc/mdr586 | - |
dc.identifier.scopusid | 2-s2.0-84864922628 | - |
dc.identifier.wosid | 000306924400030 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, v.23, no.8, pp.2108 - 2114 | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.citation.title | ANNALS OF ONCOLOGY | - |
dc.citation.volume | 23 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2108 | - |
dc.citation.endPage | 2114 | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | INTERFERON-ALPHA | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | E | - |
dc.subject.keywordAuthor | chromophobe type renal cell carcinoma | - |
dc.subject.keywordAuthor | papillary t | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.